Breaking News

Tris Pharma Appoints New BD VP

November 15, 2012

Berlent brings extensive industry experience

Jonathan Berlent has been appointed vice president of business development at Tris Pharma. He will lead the company’s product and technology partnering, and collaborate with branded pharmaceutical companies on their life cycle management opportunities.
 
“As Tris scales up its effort to address the growing unmet need in the industry for liquid extended release technology, Jonathan will lead business development efforts and be our point person with branded pharmaceutical companies,” said Ketan Mehta, president and chief executive officer of Tris Pharma.
 
Mr. Berlent has a combination of pharmaceutical and securities industry experience. For the past nine years, he has held various senior leadership positions in the pharmaceutical industry. Most recently, he was president of Granules USA, where he led its North American operations and successfully launched a finished dosage business platform, working with companies including Pfizer, Novartis, McNeil Consumer Health Janssen, GlaxoSmithKline, Par and Perrigo.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision